-+ 0.00%
-+ 0.00%
-+ 0.00%

Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1

PUBT·04/22/2026 20:45:07
Listen to the news
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1
  • Barinthus Biotherapeutics appointed Douglas Swirsky as chief financial officer, effective May 1, 2026.
  • Swirsky will also serve as principal accounting officer.
  • He was CFO of MaxCyte from March 2023 to March 2026.
  • Swirsky previously served as CFO and treasurer of AavantiBio until its December 2022 acquisition by Solid Biosciences.
  • Earlier roles include CEO of Rexahn Pharmaceuticals from November 2018 to November 2020.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barinthus Biotherapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-046861), on April 22, 2026, and is solely responsible for the information contained therein.